Ethical challenges of pregnancy prevention programs

Cutis

Volumn 81, Issue 6, 2008, Pages 494-500

  Bonebrake, Robert ^a   Casey, Murray J ^a   Huerter, Christopher ^a   Ngo, Binh ^b   O'Brien, Richard ^a   Rendell, Marc ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; TERATOGENIC AGENT;

ARTICLE; CONGENITAL MALFORMATION; CONTRACEPTION; DRUG CONTROL; ETHICS; FEMALE; HUMAN; LEGAL ASPECT; MALE; MANDATORY TESTING; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PATIENT RIGHT; PREGNANCY; PREGNANCY TEST;

ABNORMALITIES, DRUG-INDUCED; CONTRACEPTION; DERMATOLOGIC AGENTS; DRUG AND NARCOTIC CONTROL; FEMALE; HUMANS; MALE; MANDATORY TESTING; PATIENT EDUCATION AS TOPIC; PATIENT RIGHTS; PREGNANCY; PREGNANCY TESTS; TERATOGENS;

EID: 51049117881     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf. 2000;23:245-253.
2. Kramer JM. Managing the risks of therapeutic products: proceedings of a workshop. Pharmacoepidemiol Drug Saf. 2005;14:619-628.
3. Andrews E, Gilsenan A, Cook S. Therapeutic risk management interventions: feasibility and effectiveness. J Am Pharm Assoc (2003). 2004;44:491-500.
4. Lenz W, Knapp K. Thalidomide embryopathy [in German]. Dtsch Med Wochenschr. 1962;87:1232-1242.
5. Lenz W A short history of thalidomide embryopathy. Teratology. 1988;38:203-215.
6. McBride WG. The teratogenic action of drugs. Med J Aust. 1963;41:689-692.
7. Daemmrich A. A tale of two experts: thalidomide and political engagement in the United States and West Germany. Soc Hist Med. 2002;15:137-158.
8. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303-306.
9. Larkin M. Low-dose thalidomide seems to be effective in multiple myeloma [editorial]. Lancet. 1999;354:925.
10. Munshi NC, Barlogie B, Desikan KR, et al. Novel approaches in myeloma therapy. Semin Oncol. 1999;26(5)(suppl 13):28-34.
11. Raje N, Anderson K. Thalidomide - a revival story. N Engl J Med. 1999;341:1606-1609.
12. Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Ann Oncol. 2004;15:1151-1160.
13. Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther. 2003;25:342-395.
14. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363:1802-1811.
15. Okafor MC. Thalidomide for erythema nodosum leprosum and other applications. Pharmacotherapy. 2003;23:481-493.
16. Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153:254-273.
17. Uhl K, Cox E, Rogan R, et al. Thalidomide use in the US: experience with pregnancy testing in the STEPS programme. Drug Saf. 2006;29:321-329.
18. Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermatol. 2001;2:135-141.
19. Larsen TH, Jemec GB. Acne: comparing hormonal approaches to antibiotics and isotretinoin. Expert Opin Pharmacother. 2003;4:1097-1103.
20. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med, 1985;313:837-841.
21. Centers for Disease Control and Prevention. Birth defects caused by isotretinoin - New Jersey. MMWR Morb Mortal Wkly Rep. 1988;37:171-172, 177.
22. Dermatologic Drugs Advisory Committee. Open public hearings on NDA 18-662 Accutane (isotretinoin capsules) [transcript]. US Dept of Health and Human Services. April 26, 1988.
23. Pastuszak A, Koren G, Rieder MJ. Use of the retinoid pregnancy prevention program in Canada: patterns of contraception use in women treated with isotretinoin and etretinate. Reprod Toxicol. 1994;8:63-68.
24. Atanackovic G, Koren G. Fetal exposure to oral isotretinoin: failure to comply with the Pregnancy Prevention Program. CMAJ. 1999;160:1719-1720.
25. Anderson JE, Ebrahim S, Floyd L, et al. Prevalence of risk factors for adverse pregnancy outcomes during pregnancy and the preconception period-United States, 2002-2004. Matern Child Health J. 2006;10(suppl 5): S101-S106.
26. Cooper WO, Hickson GB, Ray WA. Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr Perinat Epidemiol. 2004;18:106-111.
27. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol. 1999;41(3, pt2):S7-S12.
28. Jesitus J. iPLEDGE now under way, despite objections. Dermatology Times. April 1, 2006. http://dtasia.advanstar.com/dtasia/News/iPLEDGE-now- under-way-despite-object ions/ArticleStandard/Article/de tail/317277. Accessed May 13, 2008.
29. Hill MJ. iPLEDGE: protecting patients or prohibiting access to care [editorial]? Dermatol Nurs. 2006; 18:124.
30. Stein G; US Food and Drug Administration. Docket: 02N-0115-Risk management of prescription drugs; public hearing comment number EC-7. http://www.fda.gov /ohrms/dockets/dockets/02n0115/02n-0115-EC-7.htm. Published June 21, 2002. Accessed May 13, 2008.
31. Zavodny M. Fertility and parental consent for minors to receive contraceptives. Am J Public Health. 2004;94: 1347-1351.
32. McNulty PJ, Stanwood FM, Gallas SM. Parental consent for minors to receive contraceptives. Am J Public Health. 2005;95:191-192.
33. Jones RK, Boonstra H. Confidential reproductive health services for minors: the potential impact of mandated parental involvement for contraception. Perspect Sex Reprod Health. 2004;36:182-191.
34. Felix v Hoffman-La Roche Inc, 540 So2d 102, 105 (Fl 1989).
35. Gerber v Hoffman-La Roche Inc, 392 F Supp 2d 907 (SD Tx 200.5).
36. Banner v Hoffman-La Roche Inc and Roche Laboratories Inc, 891 A2d 1229 (NJ Super Ct App Div 2006).
37. Kendall C, Afable-Munsuz A, Speizer I, et al. Understanding pregnancy in a population of inner-city women in New Orleans - results of qualitative research. Soc Sci Med. 2005;60:297-311.
38. Gilliam ML, Warden M, Goldstein C, et al. Concerns about contraceptive side effects among young Latinas: a focus-group approach. Contraception. 2004;70:299-305.
39. Harvey SM, Henderson JT, Thorburn S, et al. A randomized study of a pregnancy and disease prevention intervention for Hispanic couples. Perspect Sex Reprod Health. 2004;36:162-169.
40. Solorio MR, Yu H, Brown ER, et al. A comparison of Hispanic and white adolescent females' use of family planning services in California. Perspect Sex Reprod Health. 2004;36:157-161.
41. Thorburn S, Bogart LM. African American women and family planning services: perceptions of discrimination. Women Health, 2005;42:23-39.
42. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis. 2006;21:23-29.
43. Jick SS, Kaye JA, Russmann S, et al. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception. 2006;73:566-570.
44. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost. 2005;94:17-25.
45. Wu O, Robertson L, Twaddle S, et al; Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol. 2005; 131: 80-90.
46. Mohllajee AP, Curtis KM, Martins SL, et al. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? a systematic review. Contraception. 2006;73:166-178.
47. Samuelsson E, Hedenmalm K, Persson I. Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives -an approach to specifying rates. Eur J Epidemiol. 2005;20:509-516.
48. Chaudhry V, Cornblath DR, Corse A, et al. Thalidomideinduced neuropathy. Neurology. 2002;59:1872-1875.
49. Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153:254-273.
50. Kaiser Daily Women's Health Policy. 122 pregnancies reported among women participating in Accutane iPLEDGE program, http://www.kaisernetwork.org/daily_ reports/print_report.cfm?DR_lD=46599&dr_cat=2. Published August 1, 2007. Accessed May 13, 2008.